Broadcast Date: November 13, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Immune medicines, across cancers, infectious disease, and inflammatory disease, hold our closest promise to lasting curative therapies. IsoPlexis and various researchers will speak about the shift in space and time towards ‘Smaller’ to target our most powerful single cells, in order to accelerate timelines for finding these cures. We will provide multiple new solutions that further our applications, accelerating this concept of time in medicine. We will also describe how the data from small, yet powerful cell subsets are shifting conceptions about how humans mount effective immune responses and which cells orchestrate a balanced attack. In particular, we will discuss advancements in solutions that enable all labs to detect powerful, highly active immune cell subsets, as defined by their functional proteome. These immune cell subsets are shedding light on which patients will respond to various cancer immune medicines in a more predictive fashion—because we have solved many technological limitations around the interrogation of the secretory proteins from each cell. Additionally, we’ll discuss applications for harnessing these powerful cell subsets to advance cell and gene therapies, as well as therapeutics against infectious and inflammatory diseases.

 

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

 

Produced with support from:

Isoplexis logo

Sean Mackay

Sean Mackay
CEO and Co-Founder
IsoPlexis